Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 5/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MGMT | P16455 | 2/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30683113 | 1.00 | PIN1 (0.59) | PIN1L3MBTL1PDE5ASLC6A4CNR1 | |
| SCHEMBL2496116 | 0.82 | PIN1 (0.47) | PIN1L3MBTL1PDE5AMGMTCDK1 | |
| SCHEMBL31514820 | 0.82 | CNR1 (0.43) | PIN1CNR1CNR2MAOBALDH1A1 | |
| SCHEMBL3196355 | 0.82 | CNR1 (0.43) | PIN1CNR1CNR2MAOBALDH1A1 | |
| SCHEMBL10201397 | 0.81 | PIN1 (0.59) | PIN1L3MBTL1PDE5ASLC6A4CNR1 | |
| SCHEMBL9987642 | 0.81 | PIN1 (0.59) | PIN1L3MBTL1PDE5ASLC6A4CNR1 | |
| SCHEMBL669089 | 0.81 | MGMT (0.52) | PIN1L3MBTL1MGMTCDK1CCNB1 | |
| SCHEMBL30756269 | 0.81 | PIN1 (0.59) | PIN1L3MBTL1PDE5ASLC6A4CNR1 | |
| SCHEMBL8407028 | 0.79 | PDE5A (0.57) | PIN1L3MBTL1PDE5AMGMTCDK1 | |
| SCHEMBL2489391 | 0.78 | PIN1 (0.57) | PIN1L3MBTL1PDE5ASLC6A4CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20140243257-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243257-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| US-20130157997-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157997-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-20 | — | — | US | disclosed |
| US-8354419-B2 | Benzimidazole analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354419-B2 | Benzimidazole analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110172238-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED | 2011-07-14 | — | — | US | disclosed |
| US-20110172238-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED | 2011-07-14 | — | — | US | disclosed |
| WO-2011009084-A2 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243257-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BRI3BP, BLVRB, BRIX1 | PIN1 4758/4885L3MBTL1 154/4885PDE5A 2946/4885 |
| US-20110172238-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BRI3BP, BLVRB, BRIX1 | PIN1 4758/4885L3MBTL1 154/4885PDE5A 2946/4885 |
| US-20130157997-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BRI3BP, BLVRB, BRIX1 | PIN1 4758/4885L3MBTL1 154/4885PDE5A 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.